Giorgia Querin
Research Subjects
Research Interests
Giorgia Querin has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Anthony Béhin
Institut de myologie, hôpital Pitié-Salpêtrière, Paris
2 shared publications- Gianni Sorarù
Neuromuscular Unit, Department of Neurosciences, University of Padova, Padova, Italy
2 shared publications Pierre-François Pradat
Centre référant SLA, hôpital Pitié-Salpêtrière, Paris
2 shared publicationsRabab Debs
Département des maladies du système nerveux, hôpital Pitié-Salpêtrière, Paris
2 shared publicationsTanya Stojkovic
Institut de myologie, hôpital Pitié-Salpêtrière, Paris
2 shared publicationsTimothee Lenglet
Département de neurophysiologie clinique, hôpital Pitié-Salpêtrière, Paris
2 shared publications
Latest Publications
- 7 September 2020
- Published by Elsevier in Revue Neurologique
- Vol. 176, S21
Développement de nouveaux marqueurs chez les patients SMA type III et IV
- 7 September 2020
- Published by Elsevier in Revue Neurologique
- Vol. 176, S21
Développement de nouveaux marqueurs chez les patients SMA type III et IV
- 26 March 2019
- Published by Elsevier in Revue Neurologique
- Vol. 175, S55-S56
Étude MUNIX chez des patients atteints de formes modérées d’amyotrophie spinale SMN1
- 26 March 2019
- Published by Elsevier in Revue Neurologique
- Vol. 175, S55-S56
Étude MUNIX chez des patients atteints de formes modérées d’amyotrophie spinale SMN1
- Open Access
- 10 October 2018
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 9, 844
Biomarkers of Spinal and Bulbar Muscle Atrophy (SBMA): A Comprehensive Review
Spinal and bulbar muscular atrophy (SBMA), also known as Kennedy's disease, is a rare, X-linked, late onset neuromuscular disorder. The disease is caused by a CAG trinucleotide repeat expansion in the first exon of the androgen receptor gene. It is characterized by slowly progressive lower motor neurons degeneration, primary myopathy and widespread multisystem involvement. Respiratory involvement is rare, and the condition is associated with a normal life expectancy. Despite a plethora of therapeutic studies in mouse models, no effective disease-modifying therapy has been licensed for clinical use to date. The development of sensitive monitoring markers for the particularly slowly progressing pathology of SBMA is urgently required to aid future clinical trials. A small number of outcome measures have been proposed recently, including promising biochemical markers, which show correlation with clinical disability and disease-stage and progression. Nevertheless, a paucity of SBMA-specific biomarker studies persists, delaying the development of monitoring markers for pharmaceutical trials. Collaborative efforts through international consortia and multicenter registries are likely to contribute to the characterization of the natural history of the condition, the establishment of disease-specific biomarker panels and ultimately contribute to the development of disease-modifying drugs.
- 10 October 2018
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 9, 844
Open AccessBiomarkers of Spinal and Bulbar Muscle Atrophy (SBMA): A Comprehensive Review
Spinal and bulbar muscular atrophy (SBMA), also known as Kennedy's disease, is a rare, X-linked, late onset neuromuscular disorder. The disease is caused by a CAG trinucleotide repeat expansion in the first exon of the androgen receptor gene. It is characterized by slowly progressive lower motor neurons degeneration, primary myopathy and widespread multisystem involvement. Respiratory involvement is rare, and the condition is associated with a normal life expectancy. Despite a plethora of therapeutic studies in mouse models, no effective disease-modifying therapy has been licensed for clinical use to date. The development of sensitive monitoring markers for the particularly slowly progressing pathology of SBMA is urgently required to aid future clinical trials. A small number of outcome measures have been proposed recently, including promising biochemical markers, which show correlation with clinical disability and disease-stage and progression. Nevertheless, a paucity of SBMA-specific biomarker studies persists, delaying the development of monitoring markers for pharmaceutical trials. Collaborative efforts through international consortia and multicenter registries are likely to contribute to the characterization of the natural history of the condition, the establishment of disease-specific biomarker panels and ultimately contribute to the development of disease-modifying drugs.
- Open Access
- 11 July 2016
- Published by MedCrave Group Kft. in Journal of Neurology & Stroke
- Vol. 5 (1) , 1-2
Widening the Spectrum of Extra-Neuromuscular Involvement in SBMA: Is there a Role for Brain Pathology?
- 11 July 2016
- Published by MedCrave Group Kft. in Journal of Neurology & Stroke
- Vol. 5 (1) , 1-2
Open AccessWidening the Spectrum of Extra-Neuromuscular Involvement in SBMA: Is there a Role for Brain Pathology?
- Open Access
- 27 January 2015
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 13 (1) , 17-16
Human neural stem cell transplantation in ALS: initial results from a phase I trial
We report the initial results from a phase I clinical trial for ALS. We transplanted GMP-grade, fetal human neural stem cells from natural in utero death (hNSCs) into the anterior horns of the spinal cord to test for the safety of both cells and neurosurgical procedures in these patients. The trial was approved by the Istituto Superiore di Sanità and the competent Ethics Committees and was monitored by an external Safety Board. Six non-ambulatory patients were treated. Three of them received 3 unilateral hNSCs microinjections into the lumbar cord tract, while the remaining ones received bilateral (n = 3 + 3) microinjections. None manifested severe adverse events related to the treatment, even though nearly 5 times more cells were injected in the patients receiving bilateral implants and a much milder immune-suppression regimen was used as compared to previous trials. No increase of disease progression due to the treatment was observed for up to18 months after surgery. Rather, two patients showed a transitory improvement of the subscore ambulation on the ALS-FRS-R scale (from 1 to 2). A third patient showed improvement of the MRC score for tibialis anterior, which persisted for as long as 7 months. The latter and two additional patients refused PEG and invasive ventilation and died 8 months after surgery due to the progression of respiratory failure. The autopsies confirmed that this was related to the evolution of the disease. We describe a safe cell therapy approach that will allow for the treatment of larger pools of patients for later-phase ALS clinical trials, while warranting good reproducibility. These can now be carried out under more standardized conditions, based on a more homogenous repertoire of clinical grade hNSCs. The use of brain tissue from natural miscarriages eliminates the ethical concerns that may arise from the use of fetal material. EudraCT:2009-014484-39 .
- 27 January 2015
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 13 (1) , 17-16
Open AccessHuman neural stem cell transplantation in ALS: initial results from a phase I trial
We report the initial results from a phase I clinical trial for ALS. We transplanted GMP-grade, fetal human neural stem cells from natural in utero death (hNSCs) into the anterior horns of the spinal cord to test for the safety of both cells and neurosurgical procedures in these patients. The trial was approved by the Istituto Superiore di Sanità and the competent Ethics Committees and was monitored by an external Safety Board. Six non-ambulatory patients were treated. Three of them received 3 unilateral hNSCs microinjections into the lumbar cord tract, while the remaining ones received bilateral (n = 3 + 3) microinjections. None manifested severe adverse events related to the treatment, even though nearly 5 times more cells were injected in the patients receiving bilateral implants and a much milder immune-suppression regimen was used as compared to previous trials. No increase of disease progression due to the treatment was observed for up to18 months after surgery. Rather, two patients showed a transitory improvement of the subscore ambulation on the ALS-FRS-R scale (from 1 to 2). A third patient showed improvement of the MRC score for tibialis anterior, which persisted for as long as 7 months. The latter and two additional patients refused PEG and invasive ventilation and died 8 months after surgery due to the progression of respiratory failure. The autopsies confirmed that this was related to the evolution of the disease. We describe a safe cell therapy approach that will allow for the treatment of larger pools of patients for later-phase ALS clinical trials, while warranting good reproducibility. These can now be carried out under more standardized conditions, based on a more homogenous repertoire of clinical grade hNSCs. The use of brain tissue from natural miscarriages eliminates the ethical concerns that may arise from the use of fetal material. EudraCT:2009-014484-39 .
- 4 June 2013
- Published by Wolters Kluwer Health in Neurology
- Vol. 80 (23) , 2095-2098
Pilot trial of clenbuterol in spinal and bulbar muscular atrophy
Objective: To test the efficacy and tolerability of clenbuterol in patients with spinal and bulbar muscular atrophy (SBMA). Methods: Twenty patients with a diagnosis of SBMA were given oral clenbuterol (0.04 mg/d) for 12 months. The primary efficacy end point was the change from baseline of the walking distance covered in 6 minutes at 12 months. Secondary end points included the change over time in muscle strength assessed with the Medical Research Council scale, the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), and forced vital capacity values. Safety was assessed by a series of laboratory and instrumental tests, as well as reporting of adverse events. Results: Sixteen patients completed the study. There was a significant and sustained increase in walking distance covered in 6 minutes and forced vital capacity between the baseline and the 12-month assessments (p < 0.001). No differences were recorded in Medical Research Council or ALSFRS-R scores between baseline and follow-up assessments. Serious side effects, including those on heart function, were absent. A significant increase in serum creatine kinase levels was observed. Conclusions: Our findings suggest a positive effect of clenbuterol on SBMA disease progression. Classification of evidence: This study provides Class IV evidence that clenbuterol is effective in improving motor function in SBMA.
- 4 June 2013
- Published by Wolters Kluwer Health in Neurology
- Vol. 80 (23) , 2095-2098
Pilot trial of clenbuterol in spinal and bulbar muscular atrophy
Objective: To test the efficacy and tolerability of clenbuterol in patients with spinal and bulbar muscular atrophy (SBMA). Methods: Twenty patients with a diagnosis of SBMA were given oral clenbuterol (0.04 mg/d) for 12 months. The primary efficacy end point was the change from baseline of the walking distance covered in 6 minutes at 12 months. Secondary end points included the change over time in muscle strength assessed with the Medical Research Council scale, the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R), and forced vital capacity values. Safety was assessed by a series of laboratory and instrumental tests, as well as reporting of adverse events. Results: Sixteen patients completed the study. There was a significant and sustained increase in walking distance covered in 6 minutes and forced vital capacity between the baseline and the 12-month assessments (p < 0.001). No differences were recorded in Medical Research Council or ALSFRS-R scores between baseline and follow-up assessments. Serious side effects, including those on heart function, were absent. A significant increase in serum creatine kinase levels was observed. Conclusions: Our findings suggest a positive effect of clenbuterol on SBMA disease progression. Classification of evidence: This study provides Class IV evidence that clenbuterol is effective in improving motor function in SBMA.